Propanc Biopharma, Inc.

Listed Company

PPCBCIK 0001517681NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Jun 30

Period

FY 2025

Revenue

—

Net Income

$-58.92M

Total Assets

$19.63M

Equity

$13.91M

Shares Out

56.96M

Op. Cash Flow

$-405.2K

PPCB$1.47−51.00% · past yearDBEQ Basic

Daily closing prices

Business

Propanc Biopharma is a biopharmaceutical company developing PRP, a pancreatic proenzyme therapy for solid tumors including pancreatic, ovarian, and colorectal cancers. The lead candidate is a formulation of trypsinogen and chymotrypsinogen administered intravenously, currently in preclinical development with Phase Ib trials planned for late 2026. The company also operates the POP1 joint research program with Spanish universities to develop synthetic recombinant proenzymes and backup compounds. Propanc operates globally through Australia and UK subsidiaries.

Summary from 10-K filed 2025-09-29

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Administration expenses	57	1	1	2	2
Occupancy expenses - related party	26,560	34,150	28,841	28,366	28,112
Research and development	223,721	248,102	247,919	256,052	230,956
TOTAL OPERATING EXPENSES	57	2	2	2	2
LOSS FROM OPERATIONS	−57	−2	−2	−2	−2
Interest expense	−563,757	−665,841	−532,821	—	—
Interest income	9	60	36	5,613	—
Derivative expense	−333,596	−141,012	—	—	—
Change in fair value of derivative liabilities	212,450	316,537	−530,330	−99,111	−8,186
Gain (loss) on extinguishment of debt, net	−871,032	54,565	25,969	−17,503	50,607
Foreign currency transaction gain (loss)	−89,243	22,080	5,885	−42,395	30,497
TOTAL OTHER INCOME (EXPENSE), NET	−2	−413,611	−1	−722,194	−327,219
LOSS BEFORE TAXES	−59	−2	−3	−3	−2
Tax benefit	—	129,132	129,841	54,977	113,415
NET LOSS	−59	−2	−3	−3	−2
Deemed Dividend	—	−192,960	−466,273	−700,340	−391,749
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	−59	−2	−3	−3	−2
BASIC NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS	−14.85	−1,421	−1.8	−49.23	−0.8
DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS	−14.85	−1,421	−1.8	−49.23	—
BASIC WEIGHTED AVERAGE SHARES OUTSTANDING	4	1,417	2	68,219	3
DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING	4	1,417	2	68,219	—
Unrealized foreign currency translation gain (loss)	49,336	−25,295	60,327	149,345	−182,467
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	49,336	−25,295	60,327	149,345	−182,467
TOTAL COMPREHENSIVE LOSS	−59	−2	−3	−3	−3

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2025 2025-04-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30
Cash	12,088	—	21,085	10,047	4,067
GST tax receivable	5,302	—	2,950	2,867	—
Prepaid expenses - current portion	8	—	—	—	—
Other current assets	1,380	—	1,406	—	—
TOTAL CURRENT ASSETS	8	—	25,441	19,039	15,030
Deferred offering costs	291,773	—	27,117	—	—
Prepaid expenses - long-term portion	11	—	—	—	—
Security deposit - related party	1,971	—	2,008	1,999	2,075
Operating lease right-of-use assets, net - related party	59,413	62,126	17,799	—	62,523
TOTAL ASSETS	20	—	72,365	60,328	81,651
Accounts payable	1	—	1	966,718	943,023
Accrued expenses and other payables	1	—	792,190	579,707	466,115
Accrued interest	190,795	—	94,612	44,709	57,822
Notes payable, net of discount	543,312	—	204,694	—	—
Convertible notes, net of discounts and including put premiums	537,921	—	399,325	390,539	926,438
Embedded conversion option liabilities	403,892	—	133,886	423,209	151,262
Employee benefit liability	667,901	—	639,371	587,618	415,799
TOTAL CURRENT LIABILITIES	6	—	4	3	3
Loan payable - long-term - related party, net of discount	105,627	—	58,642	—	—
TOTAL NON-CURRENT LIABILITIES	147,376	—	58,642	19,278	42,319
TOTAL LIABILITIES	6	—	4	3	3
Commitments and Contingencies (See Note 9)	—	—	—	—	—
Common stock, $0.001 par value; 10,000,000,000 shares authorized;11,611,782 and 7,980 shares issued and outstanding as of June 30, 2025 and 2024, respectively	11,612	—	8	6,031	220
Common stock issuable (7,750 and 0 shares as of June 30, 2025 and 2024, respectively)	8	—	—	1,621	20
Additional paid-in capital	138	—	62	60	57
Accumulated other comprehensive income	1	—	1	1	1
Accumulated deficit	−126	—	−67	−65	−62
Treasury stock ($0.001 share)	−46,477	—	−46,477	−46,477	−46,477
TOTAL STOCKHOLDERS EQUITY (DEFICIT)	14	—	−4	−3	−3
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT)	20	—	72,365	60,328	81,651

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30
Issuance of common stock for services	51	—	138,948	314,626	125,572
Amortization of prepaid stock based expenses	5	—	2,408	72,513	82,872
Foreign currency transaction loss (gain)	89,243	−22,080	−5,885	42,395	−30,497
Depreciation expense	—	297	1,665	1,993	1,993
Allowance on refundable advance deposit	—	120,958	—	—	—
Amortization of debt discounts	303,563	294,005	202,952	47,971	136,527
Amortization of right-of-use assets	20,187	21,359	21,266	3,678	—
Non-cash interest expense	5,519	3,832	1,838	2,250	16,500
Accretion of put premium	—	279,711	232,674	452,308	200,410
GST receivable	−2,405	−71	−610	1,660	−2,147
Prepaid expenses and other current assets	1,379	4,746	—	—	—
Refundable advance deposit	—	−120,958	—	—	—
Deferred offering costs	—	−25,000	—	—	—
Accounts payable	187,732	242,408	80,975	18,870	178,311
Employee benefit liability	40,184	49,196	186,912	29,907	33,134
Accrued expenses and other payables	677,889	209,962	130,511	65,017	152,861
Accrued interest	255,155	78,733	92,474	63,878	80,582
Operating lease liability	−21,722	−21,598	−19,857	−3,277	—
NET CASH USED IN OPERATING ACTIVITIES	−405,168	−935,118	−1	−1	−1
Proceeds from convertible promissory notes, net of original issue discounts and issue costs	222,500	567,050	590,250	766,500	325,000
Repayment of convertible note	−8,000	−142,909	—	—	−43,000
Repayment of notes	−122,788	—	—	—	—
Proceeds from the sale of common stock	—	23,057	24,711	99,285	—
Proceeds from note payable	320,000	190,000	—	—	—
Proceeds from loans payable	—	79,811	—	—	—
Proceeds from loans payable - related parties	343,700	224,885	—	—	—
Deferred offering costs	−264,656	—	—	—	—
NET CASH PROVIDED BY FINANCING ACTIVITIES	490,756	941,894	1	1	1
Effect of exchange rate changes on cash	−94,585	4,262	−2,488	−52,670	22,468
NET INCREASE (DECREASE) IN CASH	−8,997	11,038	5,980	1,812	−64,752
Interest	30,715	9,491	2,883	2,392	13,621
Income Tax	—	—	—	—	—
Reduction of put premium related to conversions of convertible notes	10,229	246,254	—	—	—
Conversion of convertible notes and accrued interest to common stock	79,686	560,483	—	—	—
Settlement of accounts payable for shares of common stock	129,354	—	—	—	—
Settlement of loans to former director for shares of common stock	74,395	—	—	—	—
Settlement of loans payable including accrued interest for shares of common stock	86,248	—	—	—	—
Debt discounts related to derivative liability	222,500	150,000	93,668	—	—
Operating lease right-of-use asset and operating lease liability pursuant to ASC 842	62,126	—	—	—	—
Relative fair value of warrant granted in connection with a loan payable - related party	—	141,084	—	—	—
Issuance of common stock for prepaid services (net of amortized portion)	19	—	—	—	—
Deemed dividend upon alternate cashless exercise of warrants	—	192,960	466,273	700,340	391,749

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Propanc Biopharma, Inc.'s CIK number?

Propanc Biopharma, Inc.'s SEC CIK number is 0001517681 (1517681). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Propanc Biopharma, Inc.'s SEC filings?

All of Propanc Biopharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

Look up any company's CIK number →